CA2115606A1 - Intraocular irrigating and enucleated eyeball preservative composition - Google Patents
Intraocular irrigating and enucleated eyeball preservative compositionInfo
- Publication number
- CA2115606A1 CA2115606A1 CA002115606A CA2115606A CA2115606A1 CA 2115606 A1 CA2115606 A1 CA 2115606A1 CA 002115606 A CA002115606 A CA 002115606A CA 2115606 A CA2115606 A CA 2115606A CA 2115606 A1 CA2115606 A1 CA 2115606A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- eyeball
- enucleated
- intraocular irrigating
- preservative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Abstract
ABSTRACT OF THE INVENTION
This invention relates to an intraocular irrigating and enucleated eyeball preservative composition containing a phosphoric acid diester compound of the following formula or a pharmacologically acceptable salt thereof wherein R1 and R2 are the same or different and each represents a hydrogen atom or a methyl group.
The composition of this invention is highly lenient to the ocular tissues, particularly in the sense that it protects the corneal (endothelial) cells which are most susceptible to physiological damage in ophthalmic surgery, with the result that various ophthalmic operations can be carried out with sufficient safety. Furthermore, since the composition of this invention may be help retain the physiological functions of the enucleated eyeball without injuring its tissues, it can be used with advantage for the preservation of the cornea, retina, crystalline lens and so on.
This invention relates to an intraocular irrigating and enucleated eyeball preservative composition containing a phosphoric acid diester compound of the following formula or a pharmacologically acceptable salt thereof wherein R1 and R2 are the same or different and each represents a hydrogen atom or a methyl group.
The composition of this invention is highly lenient to the ocular tissues, particularly in the sense that it protects the corneal (endothelial) cells which are most susceptible to physiological damage in ophthalmic surgery, with the result that various ophthalmic operations can be carried out with sufficient safety. Furthermore, since the composition of this invention may be help retain the physiological functions of the enucleated eyeball without injuring its tissues, it can be used with advantage for the preservation of the cornea, retina, crystalline lens and so on.
Description
TITLE OF '~ INVENTION
Intraocular irrigating and enucleated eyeball preservative composition BACKGROUND OF ~ INVENT~ON
1. Field of the Invention This invention relates to a useful intraocular irrigating and enucleated eyeball preservative composition. More particularly, this invention relates to a useful intraocular irrigating and enucleated eyeball preservative composition containing an ascorbyl tocopheryl phosphate compound or a pharmacologically acceptable salt thereof.
Intraocular irrigating and enucleated eyeball preservative composition BACKGROUND OF ~ INVENT~ON
1. Field of the Invention This invention relates to a useful intraocular irrigating and enucleated eyeball preservative composition. More particularly, this invention relates to a useful intraocular irrigating and enucleated eyeball preservative composition containing an ascorbyl tocopheryl phosphate compound or a pharmacologically acceptable salt thereof.
2. Description of the Prior Art With the recent progress and spread of ophthalmic surgery, inclusive of cataract surgery and operations for transplantation of the cornea, iris or vitreous body, there is a great need for satisfactory intraocular irrigating solutions for protecting the intraocular tissues in such operative procedures. If only inadequate provisions are available for the protection of intraocular tissues in ophthalmic operations and the tissues sustain physiological damage, the postoperative courses will be unfavorable with corneal opacity, glaucoma and retinitis ensuing at times. As the intraocular irrigating solution, one :
,, .
. .
.: .
2 1 ~
close ~o physiologic aqlleous in coMposition is o-f course preferred but generally, so far~ physiological saline, lactated Ringer's solution, BSS (Balanced Salt Solution) (trade name) and BSS PLUS (trade name) have been mostly employed for intraocular irrigation.
However, these intraocular irrigating solutions are not effective enough to protect corneal (endothelial) cells which are most liable to sustain physiological damage in ophthalmic operations. Under the circumstances, the development of intraocular irrigating solutions with an improved functionality to protect the intraocular tissues, particularly corneal (endothelial) cells, has been awaited in earnest.
Meanwhile, in an operation for the implantation of an ocular tissue graft such as the cornea, retina or crystalline lens, the ocular tissue graft material isolated from a donor must be preserved in such a manner that it may retain its physiological function until it has been ultimately transplanted in a recipient. A number of enucleated eyeball preservatives have heretofore been proposed for upholding the physiological competence of enucleated globes but their efficacies insure a preservation period only about 2 weeks at most. For example, in Japan a glucose phosphate Ringer's solution containing 3.5% of dextran is in common use as a globe preservative today but the dextran (DX) penetrates into the cor-nea (epithelium, stroma and endothelium) in an early stage of preservation (within a few days) to draw :
:-., ~
. , j , "
.
. :, 211~606 in ~-ater into the tissues and reportedly induce marked corneal swelling. Moreover, it is reported that dextran weakens the joint between the corneal endothelium and Descemet's membrane to cause a hypofunction of endothelial cells. Accordingly, enucleated eyeball preservatives, typically those containing chondroitin sulfate (CS) instead of dextran, are being explored for development but none have overcome the above-mentioned disadvantages. After all, there is no eyeball preservative available today that is fully satisfactory.
Under the circumstances described above, the inventors of this invention explored the efficacies of ascorbyl tocopheryl phosphate compounds and their pharmacologically acceptable salts and discovered that these compounds have an excellent intraocular tissue-protecting action. Starting from the finding, the inventors did further research and arrived at an intraocular irrigating and enucleated eyeball preservative composition which is disclosed in this specification and claimed.
SUMMARY OF TnE INVENTION
This invention relates to an intraocular irrigating and enucleated eyeball preservative composition containing a phosphoric acid diester compound of the following formula or a pharmacologically acceptable salt thereo-f (hereinafter .
:.:. ". : ~
:.' :, . -,~.,~,. ..
~ . :
:~, i~
211~0~
re~erred to as t}le present compound) r C- ~ ~ ~ (CH2CH2CH2CH)3-CH3 L C- OH OH R
CH
¢H-OH
(wherein Rl and Rz are the same or different and each represents a hydrogen atom or a methyl group).
BRIEF DESCRIPTION OF TnE DRAWINGS
Fig. 1 is the tracing of a scanning electron microphotograph of corneal endothelial cells after the use of the composition of this invention in Experimental Example 1.
Fig. 2 is the tracing of a scanning electron microphotograph of corneal endothelial cells after the use of the composition excluding the present compound in Experimental Example 1.
DETAILED DESCRIPTION OF THE INVENTION
The present compound to be used in the intraocular irrigating and enucleated eyeball preservative composition of this invention can be synthesized by the processes described in or suggested in, inter alia, Japanese Patent (JP) Publication Hei-2-44478 and JP
,: . . ,: . .
:, .
,.... .. . ~- . :
, ~: ~ : :
,, ~.
, ,., ~: :
, 211~6~ ~
Hei-5-23274.
The present compound -for use in the intraocular irrigating and enucleated eyeball preservative composition of this invention is already known to be of value as an anticataract drug, a prophylactic and therapeutic drug for climacteric disturbance, a skin-beautifying cosmetic ~JP Publication Hei-2-44478), an anti-inflammatory drug (JP Publication Hei-1-27004), an antiulcer drug (JP Kokai Sho-63-27062) and a prophylactic and therapeutic agent for ischemic disorder in organs (JP Kokai Hei-2-111722), for instance.
However, it has not been known to this day that the present compound is of use as an active ingredient of intraocular irrigating fluids or enucleated eyeball preservative compositions.
The present compound represented by the above formula, either the free acid form or a pharmacologically acceptable salt thereof, can be used for the object of the present invention. The salt may be an alkali metal salt such as the sodium salt and the potassium salt, or an alkaline earth metal salt such as the calcium salt and the magnesium salt.
The intraocular irrigating and enucleated eyeball preservative composition of this invention may contain any one or, if necessary, more than one species of the present compound depending on the intended use and need.
The intraocular irrigating and enucleated eyeball ., , .- .
: ~-:
.
''.`''-~:, :. .
, ~ .
, ~
211~6~6 I)reSerVatiVe ('OlllpOSitiOn Or t}l.iS invcntiorl can be provided in a liquid form or in a solid ~orm for extemporaneous reconstitution. The solid composition is preferably dissolved, suspended or emulsified in purified water, physiological saline or the like. The solid composition includes such as dosage forms as tablets, granules and powders, all of which can be manufactured by the per se known procedures.
Preferably, these preparation are sterilized by known procedures such as filtration through a bacterial filter and autoclaving.
The present compound to be used in the intraocular irrigating and enucleated eyeball preservative composition of this invention is sparingly toxic and, therefore, safe clinically, wherefore it can be put to use with advantage on the occasion of various ~ ;
ophthalmic operations and for the preservation of enucleated eyeballs. [LD~o of the sodium salt of phosphoric acid diester of L-ascorbic acid, DL~a -tocopherol (hereinafter referred to briefly as EPC-Na):
Per os > 10 g/kg (rat), Subcutaneous administration >
793 mg/kg (rat)].
The recommended concentration of the present compound in the present composition for intraocular irrigation depends on species of the compound but is generally in the range of about 0.01 ~ g/ml to about 200 ~ g/ml, preferably about 0.5 ~ g/ml to about 10 g/ml, as the final concentration.
The dosage of the present compound contained in .~. .
,: :, 211~fi~
~he preserl~ composition for the prescrvat;ioll of isolated eyeballs is also dependent on species or the compound, condition of the eyeball, preservation temperature and required preservation time but is generally about 5 x 10-~ g/ml to 5 x 10-3 g/ml and preferably about 5 x 10-8 g/ml to 5 x 10-5 g/ml as the final concentration.
The pH of a liquid form of the intraocular irrigating and enucleated eyeball preservative composition of this invention is preferably adjusted to about 6.5 to 7.5 by the ~ se known procedure.
The osmotic pressure ratio of a ]iquid form of the composition of this invention is preferably controlled at about 0.5 to 3 and, for still better results, about 0.8 to 2 by the per se known procedure. The pH of the liquid is preferably adjusted to about 3 to 10 and, for still better results, about 4 to 9.
For use as an intraocular irrigating composition, the composition of this invention may contain, unless contrary to the object of the invention, various other components which are usually included in intraocular irrigating solutions, e.g. electrolytes such as calcium chloride, magnesium chloride, magnesium sulfate, sodium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium hydrogen carbonate, e.t.c., monosaccharides such as glucose e.t.c., peptides such as glutathione and glutathione disulfide, and antibiotics such as penicillin G etc. in appropriate amounts.
:,,,i,:
` ~
~'' ' ' ''' ~`" ~ ' ' ;
~,~
~ ' ~
21156~
For use of the composition of this inverltion as an eyeball preservative composition, the composition may contain, unless contrary to the object of this invention, a variety of other components which are usua]ly incorporated in eyeball preservative products, e.g. nutrients, an isotonizing agent, a pH control agent, preservatives, solubilizers, a rheology modifier, etc., in appropriate amounts. Among such components may be reckoned sugars, salts, amino acids and organic acids. The sugars may be sucrose, glucose, lactose, dextrose, mannitol and so on. The salts include sodium chloride, sodium citrate, sodium phosphate, etc. The amino acids may be glycine, glutamic acid, lysine and so on. The organic acids include citric acid, acetic acid, lactic acid an so on.
Unless contrary to the object of the invention, the enucleated eyeball preservative of this invention may further contain other medicinal substances, such as irnmunosuppressants, antibiotics, therapeutic agents for ischemic diseases, etc., in appropriate amounts.
The proper eyeball preservation temperature with the composition of this invention as an enucleated eyeball preservative is dependent on species and dosage of the present compound, condition of the eyeball and required preservation time, among other conditions, but is generally about -5 C to 20 C and preferably about O C to 15-C.
For use of the composition of this invention as an enucleated eyeball preservative, the enucleated eyeball . , - . , .."
. ~ , ' .:
:, ~
2 ~
may be preserved as it is or any t.issues of the e~-eball, such as the sclerocornea, retina or crystalline lens, may be independently preserved, the choice depending on the intended operation.
In preserving the enucleated eyeball with the composition of this invention, the conventional eyeball preservation container and other hardware can be util:ized.
E~AMPLES
The following experimental and working examples are intended to describe the invention in further detail.
tExperimental Example 1] Cornea-protecting effect of the present compound In order to evaluate the cornea tissue-protec-ting effect of L-ascorbyl DL-a -tocopheryl phosphate monopotassium (hereinafter referred to briefly as EPC-K), compositions with and without EPC-K were prepared and their protective effects on endothelial cell.s were compared using rabbit sclerocorneal sections.
[test Materials]
The test was performed using the composition containing EPC-K and the composition excluding EPC-K
from the like formulation as shown below in Example 1.
[Methodl Six male Japanese white rabbits without ocular abnormalities were used. After sacrifice of the :. : . .
.
, .
, ~ , . . . ..
,- - ~ ~ : . ~ . - . -.-. - ~ : , .
,, ~, . ' :
2115~0~
animals, the eyeballs were enucleated and sclerocorneal sections were prepared. Six eyes were ass:igned to the EPC-K-containing composition and the remaining six eyes to the EPC-K-free composition. The sclerocorneal sections were respectively placed in the wells of a 6-well plate and the test composition was placed in each well. The plate was stored at 4 C and the composition ~;
was replaced with the fresh one on a daily basis.
After 7 days, the cornea was fixed and endothelial specimens were prepared for scanning electron microscopy. The endothelium was then photographed and the hexagonal cells were counted to find its percentage.
[Results]
As shown in Table 1, microscopic observation revealed that with the formula containing EPC-K, the percentage of hexagonal cells was higher, indicating a greater cornea protecting effect (cf. Figs 1 and 2).
As clearly seen from Fig. 1, the composition of this invention caused little degeneration of hexagonal cells, with the variation of cell size being also smaller than in the control group. It can also be seen from Fig. 2 that when the composition not containing the present compound was used, normally hexagonal cells underwent degeneration, as epitomized by the cell indicated by the arrowmark in the center, with the prominent appearance of polygonal and giant cells.
Table 1 Percentage of ~exagonal cells .
., 21l 56~
Formulation containing EPC-K 70.8~- 3.8*
Formulation without EPC K 65.5~ 4.5 *: Significantly different from the control group (p<0.05) [E~ample 1]
According to the following formula, an intraocular irrigating and enucleated eyeball preservative composition is manufactured by the per se known steri]e procedure.
EPC-K 70.6 ~ g Sodium chloride 0.775 g Potassium chloride 0.041 g Calcium chloride dihydrate 0.0172 g Magnesium sulfate heptahydrate 0.0218 g Sodium dihydrogen phosphate 0.016 g Disodium monohydrogen phosphate 0.1031 g Sodium citrate 0.09 g Glucose 0.782 g Chondroitin sulfate Na 2.5 g Penicillin G 20,000 U
Purified water q.s.
Total 100 ml pH 7.43 Example 2]
According to the following formula, an intraocular irrigating and enucleated eyeball preservative -. ~ .
~.
~' ~
~::
21156~6 composition is manufactured by the per se known sterile procedure.
EPC-K 0.1 mg ;
Sodium chloride 0.66 g ;
Potassium chloride 0.036 g Potassium chloride dihydrate 0.018 g Magnesium sulfate heptahydrate 0.03 g Sodium hydrogen carbonate 0.25 g Citric acid 0.08 g Sodium acetate trihydrate 0.06 g Glucose 0.15 g Sodium hydroxide q.s.
Hydrochloric acid q.s.
Purified water q.s.
Total 100 ml pH 6.6 [Example 31 According to the following formula, a sterile ~-solid composition and a sterile liquid composition are manufactured. The solid composition is extemporaneously dissolved in the liquid composition.
(1) Liquid composition Sodium chloride 0.7 g Calcium chloride 0.04 g Calcium chloride dihydrate 0.02 g Magnesium sulfate heptahydrate 0.03 g Sodium hydrogen carbonate 0.3 g Citric acid 0.1 g Sodium acetate trihydrate 0.1 g :" ' ' , :
211$6~
Sodium hydroxide q.s.
Hydrochloric acid q.s.
Purified water q.s.
- Total 100 ml pH 7.3 (2) Solid composition EPC-K 1 mg Glucose 0.15 g ~v?,~ :
,.~ .
;': ' ' ' : , :
,: ..
' .~' ' :: ' :
j7. ' ~ : :
,, .
. .
.: .
2 1 ~
close ~o physiologic aqlleous in coMposition is o-f course preferred but generally, so far~ physiological saline, lactated Ringer's solution, BSS (Balanced Salt Solution) (trade name) and BSS PLUS (trade name) have been mostly employed for intraocular irrigation.
However, these intraocular irrigating solutions are not effective enough to protect corneal (endothelial) cells which are most liable to sustain physiological damage in ophthalmic operations. Under the circumstances, the development of intraocular irrigating solutions with an improved functionality to protect the intraocular tissues, particularly corneal (endothelial) cells, has been awaited in earnest.
Meanwhile, in an operation for the implantation of an ocular tissue graft such as the cornea, retina or crystalline lens, the ocular tissue graft material isolated from a donor must be preserved in such a manner that it may retain its physiological function until it has been ultimately transplanted in a recipient. A number of enucleated eyeball preservatives have heretofore been proposed for upholding the physiological competence of enucleated globes but their efficacies insure a preservation period only about 2 weeks at most. For example, in Japan a glucose phosphate Ringer's solution containing 3.5% of dextran is in common use as a globe preservative today but the dextran (DX) penetrates into the cor-nea (epithelium, stroma and endothelium) in an early stage of preservation (within a few days) to draw :
:-., ~
. , j , "
.
. :, 211~606 in ~-ater into the tissues and reportedly induce marked corneal swelling. Moreover, it is reported that dextran weakens the joint between the corneal endothelium and Descemet's membrane to cause a hypofunction of endothelial cells. Accordingly, enucleated eyeball preservatives, typically those containing chondroitin sulfate (CS) instead of dextran, are being explored for development but none have overcome the above-mentioned disadvantages. After all, there is no eyeball preservative available today that is fully satisfactory.
Under the circumstances described above, the inventors of this invention explored the efficacies of ascorbyl tocopheryl phosphate compounds and their pharmacologically acceptable salts and discovered that these compounds have an excellent intraocular tissue-protecting action. Starting from the finding, the inventors did further research and arrived at an intraocular irrigating and enucleated eyeball preservative composition which is disclosed in this specification and claimed.
SUMMARY OF TnE INVENTION
This invention relates to an intraocular irrigating and enucleated eyeball preservative composition containing a phosphoric acid diester compound of the following formula or a pharmacologically acceptable salt thereo-f (hereinafter .
:.:. ". : ~
:.' :, . -,~.,~,. ..
~ . :
:~, i~
211~0~
re~erred to as t}le present compound) r C- ~ ~ ~ (CH2CH2CH2CH)3-CH3 L C- OH OH R
CH
¢H-OH
(wherein Rl and Rz are the same or different and each represents a hydrogen atom or a methyl group).
BRIEF DESCRIPTION OF TnE DRAWINGS
Fig. 1 is the tracing of a scanning electron microphotograph of corneal endothelial cells after the use of the composition of this invention in Experimental Example 1.
Fig. 2 is the tracing of a scanning electron microphotograph of corneal endothelial cells after the use of the composition excluding the present compound in Experimental Example 1.
DETAILED DESCRIPTION OF THE INVENTION
The present compound to be used in the intraocular irrigating and enucleated eyeball preservative composition of this invention can be synthesized by the processes described in or suggested in, inter alia, Japanese Patent (JP) Publication Hei-2-44478 and JP
,: . . ,: . .
:, .
,.... .. . ~- . :
, ~: ~ : :
,, ~.
, ,., ~: :
, 211~6~ ~
Hei-5-23274.
The present compound -for use in the intraocular irrigating and enucleated eyeball preservative composition of this invention is already known to be of value as an anticataract drug, a prophylactic and therapeutic drug for climacteric disturbance, a skin-beautifying cosmetic ~JP Publication Hei-2-44478), an anti-inflammatory drug (JP Publication Hei-1-27004), an antiulcer drug (JP Kokai Sho-63-27062) and a prophylactic and therapeutic agent for ischemic disorder in organs (JP Kokai Hei-2-111722), for instance.
However, it has not been known to this day that the present compound is of use as an active ingredient of intraocular irrigating fluids or enucleated eyeball preservative compositions.
The present compound represented by the above formula, either the free acid form or a pharmacologically acceptable salt thereof, can be used for the object of the present invention. The salt may be an alkali metal salt such as the sodium salt and the potassium salt, or an alkaline earth metal salt such as the calcium salt and the magnesium salt.
The intraocular irrigating and enucleated eyeball preservative composition of this invention may contain any one or, if necessary, more than one species of the present compound depending on the intended use and need.
The intraocular irrigating and enucleated eyeball ., , .- .
: ~-:
.
''.`''-~:, :. .
, ~ .
, ~
211~6~6 I)reSerVatiVe ('OlllpOSitiOn Or t}l.iS invcntiorl can be provided in a liquid form or in a solid ~orm for extemporaneous reconstitution. The solid composition is preferably dissolved, suspended or emulsified in purified water, physiological saline or the like. The solid composition includes such as dosage forms as tablets, granules and powders, all of which can be manufactured by the per se known procedures.
Preferably, these preparation are sterilized by known procedures such as filtration through a bacterial filter and autoclaving.
The present compound to be used in the intraocular irrigating and enucleated eyeball preservative composition of this invention is sparingly toxic and, therefore, safe clinically, wherefore it can be put to use with advantage on the occasion of various ~ ;
ophthalmic operations and for the preservation of enucleated eyeballs. [LD~o of the sodium salt of phosphoric acid diester of L-ascorbic acid, DL~a -tocopherol (hereinafter referred to briefly as EPC-Na):
Per os > 10 g/kg (rat), Subcutaneous administration >
793 mg/kg (rat)].
The recommended concentration of the present compound in the present composition for intraocular irrigation depends on species of the compound but is generally in the range of about 0.01 ~ g/ml to about 200 ~ g/ml, preferably about 0.5 ~ g/ml to about 10 g/ml, as the final concentration.
The dosage of the present compound contained in .~. .
,: :, 211~fi~
~he preserl~ composition for the prescrvat;ioll of isolated eyeballs is also dependent on species or the compound, condition of the eyeball, preservation temperature and required preservation time but is generally about 5 x 10-~ g/ml to 5 x 10-3 g/ml and preferably about 5 x 10-8 g/ml to 5 x 10-5 g/ml as the final concentration.
The pH of a liquid form of the intraocular irrigating and enucleated eyeball preservative composition of this invention is preferably adjusted to about 6.5 to 7.5 by the ~ se known procedure.
The osmotic pressure ratio of a ]iquid form of the composition of this invention is preferably controlled at about 0.5 to 3 and, for still better results, about 0.8 to 2 by the per se known procedure. The pH of the liquid is preferably adjusted to about 3 to 10 and, for still better results, about 4 to 9.
For use as an intraocular irrigating composition, the composition of this invention may contain, unless contrary to the object of the invention, various other components which are usually included in intraocular irrigating solutions, e.g. electrolytes such as calcium chloride, magnesium chloride, magnesium sulfate, sodium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium hydrogen carbonate, e.t.c., monosaccharides such as glucose e.t.c., peptides such as glutathione and glutathione disulfide, and antibiotics such as penicillin G etc. in appropriate amounts.
:,,,i,:
` ~
~'' ' ' ''' ~`" ~ ' ' ;
~,~
~ ' ~
21156~
For use of the composition of this inverltion as an eyeball preservative composition, the composition may contain, unless contrary to the object of this invention, a variety of other components which are usua]ly incorporated in eyeball preservative products, e.g. nutrients, an isotonizing agent, a pH control agent, preservatives, solubilizers, a rheology modifier, etc., in appropriate amounts. Among such components may be reckoned sugars, salts, amino acids and organic acids. The sugars may be sucrose, glucose, lactose, dextrose, mannitol and so on. The salts include sodium chloride, sodium citrate, sodium phosphate, etc. The amino acids may be glycine, glutamic acid, lysine and so on. The organic acids include citric acid, acetic acid, lactic acid an so on.
Unless contrary to the object of the invention, the enucleated eyeball preservative of this invention may further contain other medicinal substances, such as irnmunosuppressants, antibiotics, therapeutic agents for ischemic diseases, etc., in appropriate amounts.
The proper eyeball preservation temperature with the composition of this invention as an enucleated eyeball preservative is dependent on species and dosage of the present compound, condition of the eyeball and required preservation time, among other conditions, but is generally about -5 C to 20 C and preferably about O C to 15-C.
For use of the composition of this invention as an enucleated eyeball preservative, the enucleated eyeball . , - . , .."
. ~ , ' .:
:, ~
2 ~
may be preserved as it is or any t.issues of the e~-eball, such as the sclerocornea, retina or crystalline lens, may be independently preserved, the choice depending on the intended operation.
In preserving the enucleated eyeball with the composition of this invention, the conventional eyeball preservation container and other hardware can be util:ized.
E~AMPLES
The following experimental and working examples are intended to describe the invention in further detail.
tExperimental Example 1] Cornea-protecting effect of the present compound In order to evaluate the cornea tissue-protec-ting effect of L-ascorbyl DL-a -tocopheryl phosphate monopotassium (hereinafter referred to briefly as EPC-K), compositions with and without EPC-K were prepared and their protective effects on endothelial cell.s were compared using rabbit sclerocorneal sections.
[test Materials]
The test was performed using the composition containing EPC-K and the composition excluding EPC-K
from the like formulation as shown below in Example 1.
[Methodl Six male Japanese white rabbits without ocular abnormalities were used. After sacrifice of the :. : . .
.
, .
, ~ , . . . ..
,- - ~ ~ : . ~ . - . -.-. - ~ : , .
,, ~, . ' :
2115~0~
animals, the eyeballs were enucleated and sclerocorneal sections were prepared. Six eyes were ass:igned to the EPC-K-containing composition and the remaining six eyes to the EPC-K-free composition. The sclerocorneal sections were respectively placed in the wells of a 6-well plate and the test composition was placed in each well. The plate was stored at 4 C and the composition ~;
was replaced with the fresh one on a daily basis.
After 7 days, the cornea was fixed and endothelial specimens were prepared for scanning electron microscopy. The endothelium was then photographed and the hexagonal cells were counted to find its percentage.
[Results]
As shown in Table 1, microscopic observation revealed that with the formula containing EPC-K, the percentage of hexagonal cells was higher, indicating a greater cornea protecting effect (cf. Figs 1 and 2).
As clearly seen from Fig. 1, the composition of this invention caused little degeneration of hexagonal cells, with the variation of cell size being also smaller than in the control group. It can also be seen from Fig. 2 that when the composition not containing the present compound was used, normally hexagonal cells underwent degeneration, as epitomized by the cell indicated by the arrowmark in the center, with the prominent appearance of polygonal and giant cells.
Table 1 Percentage of ~exagonal cells .
., 21l 56~
Formulation containing EPC-K 70.8~- 3.8*
Formulation without EPC K 65.5~ 4.5 *: Significantly different from the control group (p<0.05) [E~ample 1]
According to the following formula, an intraocular irrigating and enucleated eyeball preservative composition is manufactured by the per se known steri]e procedure.
EPC-K 70.6 ~ g Sodium chloride 0.775 g Potassium chloride 0.041 g Calcium chloride dihydrate 0.0172 g Magnesium sulfate heptahydrate 0.0218 g Sodium dihydrogen phosphate 0.016 g Disodium monohydrogen phosphate 0.1031 g Sodium citrate 0.09 g Glucose 0.782 g Chondroitin sulfate Na 2.5 g Penicillin G 20,000 U
Purified water q.s.
Total 100 ml pH 7.43 Example 2]
According to the following formula, an intraocular irrigating and enucleated eyeball preservative -. ~ .
~.
~' ~
~::
21156~6 composition is manufactured by the per se known sterile procedure.
EPC-K 0.1 mg ;
Sodium chloride 0.66 g ;
Potassium chloride 0.036 g Potassium chloride dihydrate 0.018 g Magnesium sulfate heptahydrate 0.03 g Sodium hydrogen carbonate 0.25 g Citric acid 0.08 g Sodium acetate trihydrate 0.06 g Glucose 0.15 g Sodium hydroxide q.s.
Hydrochloric acid q.s.
Purified water q.s.
Total 100 ml pH 6.6 [Example 31 According to the following formula, a sterile ~-solid composition and a sterile liquid composition are manufactured. The solid composition is extemporaneously dissolved in the liquid composition.
(1) Liquid composition Sodium chloride 0.7 g Calcium chloride 0.04 g Calcium chloride dihydrate 0.02 g Magnesium sulfate heptahydrate 0.03 g Sodium hydrogen carbonate 0.3 g Citric acid 0.1 g Sodium acetate trihydrate 0.1 g :" ' ' , :
211$6~
Sodium hydroxide q.s.
Hydrochloric acid q.s.
Purified water q.s.
- Total 100 ml pH 7.3 (2) Solid composition EPC-K 1 mg Glucose 0.15 g ~v?,~ :
,.~ .
;': ' ' ' : , :
,: ..
' .~' ' :: ' :
j7. ' ~ : :
Claims
1. An intraocular irrigating and enucleated eyeball preservative composition containing a phosphoric acid diester compound of the following formula or a pharmacologically acceptable salt thereof.
wherein R1 and R2 are the same or different and each represents a hydrogen atom or a methyl group.
wherein R1 and R2 are the same or different and each represents a hydrogen atom or a methyl group.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3165093 | 1993-02-22 | ||
| JP31650/1993 | 1993-02-22 | ||
| JP99416/1993 | 1993-04-26 | ||
| JP9941693 | 1993-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2115606A1 true CA2115606A1 (en) | 1994-08-23 |
Family
ID=26370155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002115606A Abandoned CA2115606A1 (en) | 1993-02-22 | 1994-02-14 | Intraocular irrigating and enucleated eyeball preservative composition |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5500445A (en) |
| EP (1) | EP0616809B1 (en) |
| KR (1) | KR100298530B1 (en) |
| AT (1) | ATE143264T1 (en) |
| CA (1) | CA2115606A1 (en) |
| DE (1) | DE69400591T2 (en) |
| ES (1) | ES2093463T3 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3362501B2 (en) * | 1994-04-28 | 2003-01-07 | 千寿製薬株式会社 | Corneal disorder treatment |
| US5795912A (en) * | 1995-04-26 | 1998-08-18 | Senju Pharmaceutical, Co., Ltd. | Therapeutic composition for corneal impairment |
| JPH09194375A (en) * | 1996-01-17 | 1997-07-29 | Senju Pharmaceut Co Ltd | Immunosuppressive effect potentiating agent |
| US20100120013A1 (en) * | 2008-11-07 | 2010-05-13 | Mb Research Laboratories, Inc. | Procedure for long term corneal culture |
| WO2017057768A1 (en) | 2015-09-30 | 2017-04-06 | 国立大学法人東北大学 | Novel antioxidizing intraocular perfusion solution |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59219295A (en) * | 1983-05-30 | 1984-12-10 | Senjiyu Seiyaku Kk | Phosphoric diester, its salt, and their preparation |
| JPS62205091A (en) * | 1986-03-04 | 1987-09-09 | Senjiyu Seiyaku Kk | Novel phosphate diester and its salt, preparation thereof and medicinal preparation containing same |
| EP0409999B1 (en) * | 1989-02-02 | 1993-09-15 | Senju Pharmaceutical Co., Ltd. | Liquid preparation for intraocular perfusion |
| WO1991003471A1 (en) * | 1989-09-11 | 1991-03-21 | Nippon Hypox Laboratories Incorporated | Ascorbic acid derivatives |
-
1994
- 1994-02-14 CA CA002115606A patent/CA2115606A1/en not_active Abandoned
- 1994-02-16 US US08/197,325 patent/US5500445A/en not_active Expired - Fee Related
- 1994-02-18 KR KR1019940002945A patent/KR100298530B1/en not_active IP Right Cessation
- 1994-02-19 ES ES94102511T patent/ES2093463T3/en not_active Expired - Lifetime
- 1994-02-19 EP EP94102511A patent/EP0616809B1/en not_active Expired - Lifetime
- 1994-02-19 AT AT94102511T patent/ATE143264T1/en not_active IP Right Cessation
- 1994-02-19 DE DE69400591T patent/DE69400591T2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0616809B1 (en) | 1996-09-25 |
| ES2093463T3 (en) | 1996-12-16 |
| US5500445A (en) | 1996-03-19 |
| KR940019300A (en) | 1994-09-14 |
| DE69400591D1 (en) | 1996-10-31 |
| ATE143264T1 (en) | 1996-10-15 |
| EP0616809A1 (en) | 1994-09-28 |
| DE69400591T2 (en) | 1997-03-06 |
| KR100298530B1 (en) | 2002-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5523316A (en) | Intraocular irrigating solution containing agent for controlling IOP | |
| US6271216B1 (en) | Stable solution of hyaluronate in a balanced salt medium | |
| US4238482A (en) | Intraocular infusion irrigation solution and method | |
| EP0414373B1 (en) | Stable solution of hyaluronate in a balanced salt medium | |
| US4837021A (en) | Two part tissue irrigating solution | |
| WO1994008602A1 (en) | Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery | |
| US5500445A (en) | Intraocular irrigating and enucleated eyeball preservative composition | |
| JP4033510B2 (en) | Ophthalmic pharmaceutical composition containing trehalose | |
| JPH0748262A (en) | Extraocular application composition | |
| Van Rij et al. | Toxic keratopathy due to the accidental use of chlorhexidine, cetrimide and cialit | |
| AU1399695A (en) | Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent | |
| EP0565897B1 (en) | Argatroban preparations for ophthalmic use | |
| ES2216318T3 (en) | PREPARATION OF IRRIGATION SOLUTION FOR OPHTHALMOLOGICAL INTERVENTION. | |
| Collin et al. | Ultrastructural changes to the corneal endothelium due to benzalkonium chloride | |
| KR100550023B1 (en) | Perfusion liquid preparations for ophthalmic operations | |
| JP3407384B2 (en) | Intraocular perfusion / cleansing agent and eyeball preservative | |
| US5380537A (en) | Single irrigating solution used in ocular therapy for the endothelium protection and cornea preservation | |
| EP0540747B1 (en) | Medicine for intraocular operation | |
| JPH0797331A (en) | Intraocular perfusate | |
| EP0628306B1 (en) | Intraocular irrigating solution containing S-(alpha,bêta-dicarboxyethyl)-glutathione | |
| US5212159A (en) | Anticataract composition | |
| Whikehart et al. | Irrigating Solutions | |
| JPS634527B2 (en) | ||
| KR20010106511A (en) | Perfusate preperation for ophthalmic operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |